Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

from http://www.syntapharma.com/about.php

Research Grants 3 show all


$12.9M
2003

$999.6K
2011

$1M
2015

Patents 1,207show all

  • 471
    C07D - Heterocyclic compounds
  • 428
    A61K - Preparations for medical, dental, or toilet purposes
  • 127
    C07C - Acyclic or carbocyclic compounds
  • 87
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 47
    Y02A - Technologies for adaptation to climate change
  • 41
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 22
    C07K - Peptides
  • 17
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 14
    C04B - Lime, magnesia
  • 9
    Y02P - Climate change mitigation technologies in the production or processing of goods

Clinical Trials 71show all

25N/A17Phase 216Phase 16Phase 35Phase 1/Phase 22Other

SEC Filings show all


123
8-K

40
10-Q

14
10-K

2
D

1
S-1

Contact Information

45 Hartwell Avenue
Lexington, MA 02421
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$217,350,00051-1002015-04-01Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2015-04-01$38,500,000Post Ipo Equity
2010-01-08$23,100,000Post Ipo Equity
2006-10-22$40,000,000Series Unknown
2004-01-14$50,000,000Series CDuquesne Capital Management, SunAmerica, Caxton Associates, Galleon Group, Gollust Management, Mountain Trail Investments
2002-05-31$12,000,000Series Unknown
2004-12-07Series D
2010-01-19$3,750,000Series Unknown
2003-04-21$50,000,000Series B

SEC Form D Funding Events

DateOfferedSoldType
2004-12-07Unknown Unknown Other (Paper Filing)